FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and tau filaments in forebrain

Molecular and Cellular Neuroscience

Volumn 18, Issue 6, 2001, Pages 702-714

  Lim, F ^a   Hernandez F ^a   Lucas, J J ^a   Gomez Ramos P ^a   Moran M A ^a   Avila J ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; TAU PROTEIN; TUBULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; CELL ULTRASTRUCTURE; CHROMOSOME 17; CONTROLLED STUDY; DEGENERATIVE DISEASE; ENZYME ACTIVITY; FOREBRAIN; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; HIPPOCAMPUS; HUMAN; HUMAN CELL; LYSOSOME; MISSENSE MUTATION; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TAUOPATHY; TRANSGENIC MOUSE;

ANIMALIA; MUS MUSCULUS;

EID: 0035680685     PISSN: 10447431     EISSN: None     Source Type: Journal    
DOI: 10.1006/mcne.2001.1051     Document Type: Article

References (53)

1. Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules
2. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease
3. Polymerization of tau peptides into fibrillar structures. The effect of FTDP-17 mutations
4. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
5. Cytosolic proteolysis of tau by cathepsin D in hippocampus following suppression of cathepsins B and L
6. Suppression of cathepsins B and L causes a proliferation of lysosomes and the formation of meganeurites in hippocampus
7. cis-acting signals and trans-acting proteins are involved in tau mRNA targeting into neurites of differentiating neuronal cells
8. Novel cathepsin D inhibitors block the formation of hyperphosphorylated tau fragments in hippocampus
9. Lysosomal protease inhibitors induce meganeurites and tangle-like structures in entorhinohippocampal regions vulnerable to Alzheimer's disease
10. Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones
11. The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region
12. Regulated phosphorylation and dephosphorylation of tau protein: Effects on microtubule interaction, intracellular trafficking and neurodegeneration
13. Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease
14. Lipofucsin: Intra- and extraneuronal accumulation and regional distribution
15. Properties of the endosomal-lysosomal system in the human central nervous system: Disturbances mark most neurons in populations at risk to degenerate in Alzheimer's disease
16. Lysosomal abnormalities in degenerating neurons link neuronal compromise to senile plaque development in Alzheimer disease
17. Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation
18. Distribution of enzymes between subcellular fractions in animal tissues
19. Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes
20. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: Implications for Alzheimer's disease
21. Tau mutations cause frontotemporal dementias
22. Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: Identification of phosphorylation sites in tau protein
23. Tau filament formation in transgenic mice expressing P301L Tau
24. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform
25. Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly
26. Untangling tau-related dementia
27. Morphology and neurochemical characteristics of the vulnerable neurons in brain aging and Alzheimer's disease
28. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17
29. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
30. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform
31. Neurodegenerative tauopathies: Human disease and transgenic mouse models
32. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein
33. Subcellular localization of tau mRNA in differentiating neuronal cell culture: Implications for neuronal polarity
34. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice
35. Endogenous serine protease inhibitor modulates epileptic activity and hippocampal long-term potentiation
36. Stable expression in Chinese hamster ovary cells of mutated tau genes causing frontotemporal dementia and parkinsonism linked to chromosome 17(FTDP-17)
37. Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes
38. Site-specific dephosphorylation of tau protein at Ser202/Thr205 in response to microtubule depolymerization in cultured human neurons involves protein phosphatase 2A
39. Overexpression of tau protein in COS-1 cells results in the stabilization of centrosome-independent microtubules and extension of cytoplasmic processes
40. Acid phosphatases
41. Difference between the tau protein of Alzheimer paired helical filament core and normal tau revealed by epitope analysis of monoclonal antibodies 423 and 7.51
42. Age-dependent neuronal and synaptic degeneration in mice transgenic for the C terminus of the amyloid precursor protein
43. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404
44. The FTDP-17-linked mutation R406W abolishes the interaction of phosphorylated tau with microtubules
45. Ferritin is associated with the aberrant tau filaments present in progressive supranuclear palsy
46. Tau is a candidate gene for chromosome 17 frontotemporal dementia
47. Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein
48. Tau protein pathology in neurodegenerative diseases
49. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia
50. Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein
51. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
52. Tau regulates the attachment/detachment but not the speed of motors in microtubule-dependent transport of single vesicles and organelles
53. Phenotypic variation in hereditary frontotemporal dementia with tau mutations